BioWorld

Feb. 24, 2004

Domantis Raises US$33M For Program In Domain Antibodies

Domantis Ltd. raised US$33 million in a Series B financing that could take the company into clinical trials with its lead domain antibody (dAb) therapeutics. (BioWorld Today) Read More

FDA Accepts Celgene's sNDA To Broaden Thalomid's Label

Scripps Scientists Level Synthetic Chemical, Cardiogenol C By Name, From Mouse Stem Cells Into Heart

Antares Intends To Raise Profile After $14.6M Private Placement

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...